Modifiable Risk Factors for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: New Approaches to Old Problems

Parsons, J. Kellogg

doi:10.1016/j.juro.2007.03.103

Cited by 184 publications

(153 citation statements)

References 51 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Mechanisms underlying this increased incidence remain unclear, although obesity and diabetes are both strongly associated with increased risks of BPH and LUTS [9][10][11], and both of these conditions have attained epidemic status in the USA over the last 15 years.…”

Section: Discussionmentioning

confidence: 99%

Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008

et al. 2011

Self Cite

View full text Add to dashboard Cite

7 464 730 (5.6%) had either a primary or secondary diagnosis of BPH.• The age-adjusted prevalence of BPH among all hospitalizations, irrespective of primary diagnosis, increased from 4.3% to 8% ( P < 0.001) during the study period.• The age-adjusted prevalence of BPH as a primary diagnosis decreased from 0.88% to 0.48% ( P < 0.001).• Discharges for BPH surgery decreased 51% (odds ratio [OR] 0.49, 95% confidence interval [CI] 0.45-0.54, P -trend < 0.001) over time. Discharges for primary BPH with acute renal failure increased > 400% (OR 4.28, 95% CI 3.22-5.71, P -trend < 0.001).• There were no significant changes in discharges for primary BPH with urinary retention ( P -trend = 0.636), bladder stones ( P -trend = 0.117), or urinary infection ( Ptrend = 0.101) over time. CONCLUSIONS• Increased hospitalizations for BPH with acute renal failure and stable hospitalizations for other AEs of BPH indicate that severe AEs of BPH persist despite widespread use of oral therapies in the USA.• Further studies are needed to explain these trends. What's known on the subject? and What does the study add? In clinical trials, oral medications for BPH have been effective at managing LUTS and preventing progression to urinary retention, urinary infections, and renal insufficiency. Population-level trends of these adverse outcomes are poorly characterized. We identified a 400% increase in hospitalizations for BPH with acute renal failure, indicating that severe adverse events of BPH persist despite widespread use of oral therapies in the USA. OBJECTIVE

show abstract

Section: Discussionmentioning

confidence: 99%

Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Scientific interest in anthropometric measurements and prostate hyperplasia has mainly been focused on height, weight and measures of weight adjusted for height, such as body mass index (BMI) with less interest in waist circumference and its ratio to hips circumference. Although a cluster of published epidemiological evidence demonstrates that obesity may increase the risks of BPH and LUTS, [3][4][5] it still lacks the quantitative evidence to certify this association. To provide a comprehensive summary of the relation between obesity and BPH risk, we use the BMI as the measure of obesity to summarize the evidence from the epidemiological literature on this issue.…”

Section: Introductionmentioning

confidence: 99%

Body mass index and risk of BPH: a meta-analysis

Wang

Mao

Lin

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

BACKGROUND: Epidemiological studies have reported conflicting results relating obesity to BPH. A meta-analysis of cohort and case-control studies was conducted to pool the risk estimates of the association between obesity and BPH.METHODS: Eligible studies were retrieved by both computer searches and review of references. We analyzed abstracted data with random effects models to obtain the summary risk estimates. Dose-response meta-analysis was performed for studies reporting categorical risk estimates for a series of exposure levels. RESULTS:A total of 19 studies met the inclusion criteria of the meta-analysis. Positive association with body mass index (BMI) was observed in BPH and lower urinary tract symptoms (LUTS) combined group (odds ratio ¼ 1.27, 95% confidence intervals 1.05-1.53). In subgroup analysis, BMI exhibited a positive dose-response relationship with BPH/LUTS in population-based case-control studies and a marginal positive association was observed between risk of BPH and increased BMI. However, no association between BPH/LUTS and BMI was observed in other subgroups stratified by study design, geographical region or primary outcome. CONCLUSIONS:The overall current literatures suggested that BMI was associated with increased risk of BPH. Further efforts should be made to confirm these findings and clarify the underlying biological mechanisms.

show abstract

“…Etiyolojik nedenler arasında metabolik sendrom, enflamasyon, büyüme faktörü, epitelyal-stromal etkileşim, androjen reseptörleri ve yaşam tarzı gibi pek çok teoriye rağmen etiyoloji halen net değildir [4].…”

Section: Etiyolojiunclassified

Benign Prostat Hiperplazisi

Danacı¹,

Fakultesi²

2018

Trd Sem

View full text Add to dashboard Cite

Modifiable Risk Factors for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: New Approaches to Old Problems

Cited by 184 publications

References 51 publications

Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008

Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008

Body mass index and risk of BPH: a meta-analysis

Benign Prostat Hiperplazisi

Contact Info

Product

Resources

About